D Tougeron

Summary

Country: France

Publications

  1. doi request reprint Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
    David Tougeron
    Affiliations of authors Department of Gastroenterology DT, gs, CS, Department of Medical Oncology AF, and Department of Molecular Oncology LKT, Poitiers University Hospital, Poitiers, France Laboratoire Inflammation, Tissus Epithéliaux et Cytokines LITEC EA 4331, Poitiers University, Poitiers DT, CS Methodology and Quality of Life in Oncology Unit, Besancon University Hospital, Besancon, France GM Department of Gastroenterology, Ambroise Pare Hospital, Boulogne Billancourt, France IT Department of Gastroenterology TL and Department of Biochemistry JCP, Tours University Hospital, Tours, France, UMR GICC CNRS 7292, Tours François Rabelais University, Tours TL Paris Descartes University, Cochin Hospital, Paris, France RC Department of Gastroenterology TA and Department of Medical Oncology CDG, Avicenne Hospital, Bobigny, France Department of Gastroenterology, Bordeaux Nord Aquitaine Clinic, Bordeaux, France CL Department of Gastroenterology, Jean Mermoz Lyon Hospital, Lyon, France PA Department of Gastroenterology, Nantes University Hospital
    J Natl Cancer Inst 108:. 2016
  2. doi request reprint Absence of IDH mutation in colorectal cancers with microsatellite instability
    David Tougeron
    EA 4331 LITEC, Laboratoire Inflammation, Tissus Epithéliaux et Cytokines Poitiers, Poitiers University, France Gastroenterology Department, Poitiers University Hospital, Poitiers, France Electronic address
    Dig Liver Dis 48:681-3. 2016
  3. doi request reprint Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study
    D Tougeron
    Department of Gastroenterology, Poitiers University Hospital, Poitiers, France Electronic address
    Eur J Cancer 51:925-34. 2015
  4. doi request reprint Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    David Tougeron
    Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Miletrie, Poitiers Cedex, France
    Cancer Chemother Pharmacol 72:397-403. 2013
  5. pmc Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers
    David Tougeron
    INSERM, U1079, Faculty of Medicine, Institute for Medical Research, Rouen University Hospital, Rouen, France
    PLoS ONE 8:e61001. 2013
  6. doi request reprint Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
    D Tougeron
    Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Miletrie, 86000 Poitiers cedex, France
    Ann Oncol 24:1267-73. 2013
  7. doi request reprint [Immune response and colorectal cancer]
    David Tougeron
    CHU de Poitiers, Service d Hepato gastro enterologie, 2, rue de la Miletrie, 86000 Poitiers cedex, France
    Bull Cancer 100:283-94. 2013
  8. doi request reprint Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital Charles Nicolle, Northwest Canceropole, France
    J Surg Oncol 105:761-6. 2012
  9. doi request reprint Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres
    David Tougeron
    Department of Gastroenterology, Poitiers University Hospital, Cancéropôle Grand Ouest, Poitiers, France
    Dig Liver Dis 44:350-4. 2012
  10. doi request reprint Management of esophageal adenocarcinoma
    D Tougeron
    Service d Hepato Gastroenterologie, CHU de Poitiers, 2, rue de la Miletrie, 86000 Poitiers cedex, France
    J Visc Surg 148:e161-70. 2011

Collaborators

Detail Information

Publications16

  1. doi request reprint Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
    David Tougeron
    Affiliations of authors Department of Gastroenterology DT, gs, CS, Department of Medical Oncology AF, and Department of Molecular Oncology LKT, Poitiers University Hospital, Poitiers, France Laboratoire Inflammation, Tissus Epithéliaux et Cytokines LITEC EA 4331, Poitiers University, Poitiers DT, CS Methodology and Quality of Life in Oncology Unit, Besancon University Hospital, Besancon, France GM Department of Gastroenterology, Ambroise Pare Hospital, Boulogne Billancourt, France IT Department of Gastroenterology TL and Department of Biochemistry JCP, Tours University Hospital, Tours, France, UMR GICC CNRS 7292, Tours François Rabelais University, Tours TL Paris Descartes University, Cochin Hospital, Paris, France RC Department of Gastroenterology TA and Department of Medical Oncology CDG, Avicenne Hospital, Bobigny, France Department of Gastroenterology, Bordeaux Nord Aquitaine Clinic, Bordeaux, France CL Department of Gastroenterology, Jean Mermoz Lyon Hospital, Lyon, France PA Department of Gastroenterology, Nantes University Hospital
    J Natl Cancer Inst 108:. 2016
    ..We assessed the efficacy of fluoropyrimidine with and without oxaliplatin in a large cohort of dMMR CC patients...
  2. doi request reprint Absence of IDH mutation in colorectal cancers with microsatellite instability
    David Tougeron
    EA 4331 LITEC, Laboratoire Inflammation, Tissus Epithéliaux et Cytokines Poitiers, Poitiers University, France Gastroenterology Department, Poitiers University Hospital, Poitiers, France Electronic address
    Dig Liver Dis 48:681-3. 2016
    ..Sporadic dMMR CRCs are due to hypermethylation MLH1 gene promoter and associated with the CpG island methylator phenotype (CIMP). Isocitrate dehydrogenase (IDH) mutant tumors are associated with DNA hypermethylation in various cancers...
  3. doi request reprint Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study
    D Tougeron
    Department of Gastroenterology, Poitiers University Hospital, Poitiers, France Electronic address
    Eur J Cancer 51:925-34. 2015
    ..Several studies have identified clinical and pathological factors predictive of recurrence in resected CRC, but not in the MSI subgroup...
  4. doi request reprint Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    David Tougeron
    Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Miletrie, Poitiers Cedex, France
    Cancer Chemother Pharmacol 72:397-403. 2013
    ..A KRAS mutation was found after anti-EGFR mAb in only one tumor. Our results suggest that acquired EGFR S492R and KRAS mutations do not constitute the main mechanism of resistance to anti-EGFR mAb in combination with chemotherapy. ..
  5. pmc Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers
    David Tougeron
    INSERM, U1079, Faculty of Medicine, Institute for Medical Research, Rouen University Hospital, Rouen, France
    PLoS ONE 8:e61001. 2013
    ..We have undertaken to determine the link between TIL densities and MSI CRC histologic features...
  6. doi request reprint Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
    D Tougeron
    Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Miletrie, 86000 Poitiers cedex, France
    Ann Oncol 24:1267-73. 2013
    ..Up until now, the impact of low-frequency KRAS mutations (<10%) on the response to anti-EGFR Mabs has yet to be evaluated...
  7. doi request reprint [Immune response and colorectal cancer]
    David Tougeron
    CHU de Poitiers, Service d Hepato gastro enterologie, 2, rue de la Miletrie, 86000 Poitiers cedex, France
    Bull Cancer 100:283-94. 2013
    ..These data should be considered for the treatment of CRC or the development of immunotherapy strategies...
  8. doi request reprint Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital Charles Nicolle, Northwest Canceropole, France
    J Surg Oncol 105:761-6. 2012
    ..Data concerning the usefulness of definitive CRT in patients with esophageal adenocarcinoma (ADC) are lacking. The aim of the study was to compare the results of definitive CRT versus surgery in patients with an ADC...
  9. doi request reprint Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres
    David Tougeron
    Department of Gastroenterology, Poitiers University Hospital, Cancéropôle Grand Ouest, Poitiers, France
    Dig Liver Dis 44:350-4. 2012
    ..The risks of chemoradiotherapy in elderly patients with rectal cancer have not yet been well-characterised...
  10. doi request reprint Management of esophageal adenocarcinoma
    D Tougeron
    Service d Hepato Gastroenterologie, CHU de Poitiers, 2, rue de la Miletrie, 86000 Poitiers cedex, France
    J Visc Surg 148:e161-70. 2011
    ..For patients with contraindications to surgery, exclusive chemoradiation therapy is recommended. Herein we reviewed and synthesized the different therapeutic strategies for esophageal adenocarcinoma...
  11. doi request reprint Unusual skeletal muscle metastasis from gastric adenocarcinoma
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, Northwest Canceropole, Rouen, France
    Gastroenterol Clin Biol 33:485-7. 2009
    ..The patient is alive and free of recurrence in the deltoid muscle after a follow-up of 13 months. Based on this case study, the difficulty of diagnosing skeletal muscle metastases, the prognosis and treatment options are discussed...
  12. doi request reprint Control of pelvic symptoms in patients with rectal cancer and synchronous metastases
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Northwest Canceropole, Rouen University Hospital, 1 rue de Germont, Rouen Cedex, France
    Gastroenterol Clin Biol 33:1106-13. 2009
    ..The optimal treatment strategy for rectal cancer (RC) with synchronous metastases remains an issue of debate. The aim of this study was to evaluate the impact of surgery and radiation on the control of pelvic symptoms in this setting...
  13. pmc Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, Northwest Canceropole, Rouen Cedex, France
    Br J Cancer 99:1586-92. 2008
    ..046) were identified as independent prognostic factors of overall survival. These results suggest that CRT could be considered as an effective treatment without major toxicity in elderly patients with OC...
  14. pmc TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
    A Oden-Gangloff
    INSERM U614, Faculty of Medicine, Institute for Biomedical Research, University of Rouen, Rouen, France
    Br J Cancer 100:1330-5. 2009
    ....
  15. doi request reprint Unusual iris metastasis from anal cancer: a case report
    D Tougeron
    Department of Hepatogastroenterology, Rouen University Hospital, Rouen, France
    Dig Liver Dis 41:e1-3. 2009
    ..Anal carcinoma can metastasize to the iris. Radiotherapy allows a good local control of tumour but the prognosis depends on systemic disease which is generally bad...
  16. doi request reprint Irreversible electroporation for locally advanced pancreatic cancer
    J P Tasu
    Department of Imaging, University Hospital of Poitiers, rue de la Miletrie, 86000 Poitiers, France Electronic address
    Diagn Interv Imaging 97:1297-1304. 2016
    ..This technique helps preserve the ducts, vessels or nerves located in the treatment area. This article reviews the current knowledge regarding the use of electroporation for the treatment of pancreatic adenocarcinoma...